LU92759I2 - Vorapaxar ou son sel solvat pharmacologiquement admissible - Google Patents

Vorapaxar ou son sel solvat pharmacologiquement admissible Download PDF

Info

Publication number: LU92759I2
Authority: LU; Luxembourg
Prior art keywords: pharmacologiquement; solvat; vorapaxar; admissible; son sel
Prior art date: 2002-04-16

Application number

LU92759C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-16

Filing date

2015-06-29

Publication date

2015-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92759(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-06-29 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2015-08-31 Publication of LU92759I2 publication Critical patent/LU92759I2/xx

Links

ZBGXUVOIWDMMJE-QHNZEKIYSA-N vorapaxar Chemical compound C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 ZBGXUVOIWDMMJE-QHNZEKIYSA-N 0.000 title 1
229960005044 vorapaxar Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU92759C 2002-04-16 2015-06-29 Vorapaxar ou son sel solvat pharmacologiquement admissible LU92759I2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37307202P	2002-04-16	2002-04-16

Publications (1)

Publication Number	Publication Date
LU92759I2 true LU92759I2 (en)	2015-08-31

Family

ID=29250954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92759C LU92759I2 (en)	2002-04-16	2015-06-29	Vorapaxar ou son sel solvat pharmacologiquement admissible

Country Status (33)

Country	Link
US (3)	US7304078B2 (fr)
EP (5)	EP1982984B1 (fr)
JP (2)	JP4558331B2 (fr)
KR (1)	KR101026929B1 (fr)
CN (1)	CN1659162B (fr)
AR (1)	AR039570A1 (fr)
AT (3)	ATE494284T1 (fr)
AU (1)	AU2003221932B2 (fr)
BR (1)	BRPI0309309B8 (fr)
CA (1)	CA2482858C (fr)
CY (3)	CY1107184T1 (fr)
DE (3)	DE60331114D1 (fr)
DK (2)	DK1495018T3 (fr)
EC (1)	ECSP045368A (fr)
ES (3)	ES2297150T7 (fr)
FR (1)	FR15C0047I2 (fr)
IL (1)	IL164585A (fr)
LT (1)	LTC1495018I2 (fr)
LU (1)	LU92759I2 (fr)
MX (1)	MXPA04010308A (fr)
MY (1)	MY144040A (fr)
NL (1)	NL300746I1 (fr)
NO (2)	NO330500B1 (fr)
NZ (2)	NZ575139A (fr)
PE (1)	PE20040412A1 (fr)
PL (1)	PL214718B1 (fr)
PT (2)	PT2065384E (fr)
RU (2)	RU2329264C9 (fr)
SG (1)	SG164279A1 (fr)
SI (2)	SI1495018T1 (fr)
TW (1)	TWI343919B (fr)
WO (1)	WO2003089428A1 (fr)
ZA (1)	ZA200408342B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
WO2005118576A1 (fr) *	2004-05-28	2005-12-15	Schering Corporation	Analogues d'himbacine contraints utilises comme antagonistes du recepteur de thrombine
CA2582353A1 (fr) *	2004-10-06	2006-04-20	University Of Rochester	Traitement de l'hypertension pulmonaire au moyen d'un agent inhibant une voie du facteur tissulaire
US20060172397A1 (en) *	2005-01-14	2006-08-03	Schering Corporation	Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
DK1848705T3 (da) *	2005-01-14	2010-06-14	Schering Corp	EXO- og diastereoselektive synteser af himbacin-analoger
AR052871A1 (es)	2005-01-14	2007-04-11	Schering Corp	Una sintesis exo-selectiva de analogos de himbacina
SG158885A1 (en) *	2005-01-14	2010-02-26	Schering Corp	Synthesis of himbacine analogs
US7541471B2 (en) *	2005-01-14	2009-06-02	Schering Corporation	Synthesis of himbacine analogs
AU2006230292A1 (en) *	2005-03-31	2006-10-05	Schering Corporation	Spirocyclic thrombin receptor antagonists
WO2007075808A2 (fr) *	2005-12-20	2007-07-05	Schering Corporation	Procedes de prevention et/ou de traitement d’un trouble de proliferation de cellules
WO2007075964A2 (fr) *	2005-12-22	2007-07-05	Schering Corporation	Antagonistes de recepteur de thrombine en tant que phophylaxie aux complications de derivation cardiopulmonaire
PE20080183A1 (es) *	2006-04-06	2008-03-10	Schering Corp	Terapias de combinacion de tra
JP2009533450A (ja) *	2006-04-13	2009-09-17	シェーリングコーポレイション	縮合環トロンビンレセプターアンタゴニスト
CA2655720A1 (fr) *	2006-06-29	2008-01-10	Schering Corporation	Antagonistes de recepteur de la thrombine bicycliques et tricycliques substitues
AR061727A1 (es) *	2006-06-30	2008-09-17	Schering Corp	Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) *	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de)	2006-08-02	2008-02-07	Sanofi-Aventis	Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
MX2009003758A (es) *	2006-10-04	2009-04-22	Schering Corp	Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina.
MX2009003761A (es) *	2006-10-04	2009-06-30	Schering Corp	Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
EP2120879A2 (fr) *	2006-12-22	2009-11-25	Schering Corporation	Promoteurs de désintégration dans des formulations de forme solide obtenues par un procédé de granulation par voie humide
MX2009010268A (es) *	2007-03-23	2009-11-09	Schering Corp	Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
CA2713551C (fr)	2008-02-05	2016-06-14	Sanofi-Aventis	Sels de triazolium en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que medicaments
MY152040A (en)	2008-02-05	2014-08-15	Sanofi Aventis	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (fr) *	2008-04-02	2009-10-08	Schering Corporation	Thérapies de combinaison comprenant des antagonistes de récepteur 1 activé par protéase (par1) associés à des antagonistes récepteur 4 activé par protéase (par4)
JP5504259B2 (ja)	2008-05-19	2014-05-28	メルク・シャープ・アンド・ドーム・コーポレーション	第ｉｘａ因子阻害剤としての複素環式化合物
SI2438060T1 (sl)	2009-06-04	2014-04-30	Merck Sharp & Dohme Corp.	Aktivni metabolit trombin receptorskega antagonista
EP2440191A2 (fr)	2009-06-08	2012-04-18	Schering Corporation	Antagoniste du récepteur de la thrombine et comprimé de clopidogrel à dose fixe
EP2462123B1 (fr)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	Dérivés de pyrimidine trisubstitués en positions 4,5,6 en tant qu' inhibiteurs du facteur ixa
ES2532902T3 (es)	2010-04-16	2015-04-01	Sanofi	Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1
PL2558462T3 (pl)	2010-04-16	2015-03-31	Sanofi Sa	Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
KR101303348B1 (ko)	2010-06-25	2013-09-03	한국화학연구원	트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (fr)	2012-03-06	2013-09-12	Merck Sharp & Dohme Corp.	Préparation et utilisation de dérivés bicycliques d'himbacine en tant qu'antagonistes du récepteur de par
EP3024550A4 (fr)	2013-07-22	2016-12-07	Merck Sharp & Dohme	Co-cristal de l'antagoniste du récepteur par-1 de vorapaxar et aspirine
WO2015026685A1 (fr) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	Dérivés bicycliques de 7a-hétérocycle substitué-6,6-difluoro himbacine
US9808473B2 (en)	2013-08-22	2017-11-07	Merck Sharp & Dohme Corp.	Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en)	2013-08-22	2017-07-11	Merck Sharp & Dohme Corp.	Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
FR3014693B1 (fr)	2013-12-16	2016-01-08	Pf Medicament	Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
WO2015160636A1 (fr)	2014-04-16	2015-10-22	Merck Sharp & Dohme Corp.	Inhibiteurs du facteur ixa
DE102014108210A1 (de)	2014-06-11	2015-12-17	Dietrich Gulba	Rodentizid
CN105985303B (zh) *	2015-02-13	2020-08-14	上海彩迩文生化科技有限公司	抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) *	2015-09-01	2017-03-08	博瑞生物医药（苏州）股份有限公司	沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) *	2015-11-25	2017-05-31	博瑞生物医药（苏州）股份有限公司	一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) *	2016-02-05	2018-03-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (fr) *	2016-02-05	2017-08-10	Sanovel Ilac Sanayi Ve Ticaret A.S.	Nouvelle composition pharmaceutique à base de vorapaxar et de métoprolol
TW201738221A (zh) *	2016-04-22	2017-11-01	Jiangsu Tasly Diyi Pharmaceutical Co Ltd	新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) *	2016-08-22	2016-12-21	孔五	一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr)	2018-12-19	2021-05-07	Cvasthera	Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) *	2019-08-02	2020-06-26	牡丹江医学院	一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) *	2019-10-21	2021-04-22	United States Government as Represented by the Department of Veteran Affairs	Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr)	2020-04-08	2023-04-14	Cvasthera	Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CA3189771A1 (fr)	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Composes utiles en tant qu'inhibiteurs du facteur xia
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (fr)	2021-04-06	2022-10-12	BIORoxx GmbH	Utilisation de composés anticoagulants comme rodenticides
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en)	2021-07-22	2025-04-29	Janssen Pharmaceutica Nv	5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr)	2022-04-08	2023-10-13	Cvasthera	Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2623810B2 (fr)	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (fr) *	1990-11-22	1993-01-01	Takeda Pharm Industry Co Ltd
GB9102862D0 (en) *	1991-02-11	1991-03-27	Erba Carlo Spa	N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en)	1994-01-31	1996-11-19	Elf Sanofi	Method for the secondary prevention of ischemic events
SK285153B6 (sk)	1997-11-25	2006-07-07	Schering Corporation	Heterocyklickou skupinou substituovaná tricyklická zlúčenina, farmaceutický prostriedok obsahujúci túto zlúčeninu a jej použitie
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
FR2779726B1 (fr)	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) *	2000-06-15	2004-09-30	Samuel Chackalamannil	Methods of use of thrombin receptor antagonists
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
KR100604742B1 (ko) *	2000-06-15	2006-07-26	쉐링 코포레이션	트롬빈 수용체 길항제
CA2463628A1 (fr)	2001-10-18	2003-04-24	Schering Corporation	Analogues d'himbacine tels que des antagonistes recepteurs de lathrombine

2003
- 2003-04-14 EP EP08012015A patent/EP1982984B1/fr not_active Expired - Lifetime
- 2003-04-14 CA CA2482858A patent/CA2482858C/fr not_active Expired - Lifetime
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 EP EP09150995A patent/EP2065384B1/fr not_active Expired - Lifetime
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/fr not_active Ceased
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 EP EP07016461A patent/EP1860106B1/fr not_active Expired - Lifetime
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko not_active Expired - Fee Related
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 EP EP03718393A patent/EP1495018B3/fr not_active Expired - Lifetime
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 EP EP09150996A patent/EP2062890B1/fr not_active Expired - Lifetime
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
2004
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
2015
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I2/el unknown

Also Published As

Publication number	Publication date
AU2003221932B2 (en)	2007-11-22
PT2065384E (pt)	2011-03-16
BRPI0309309B1 (pt)	2018-09-04
ATE455774T1 (de)	2010-02-15
RU2008106401A (ru)	2009-08-27
IL164585A0 (en)	2005-12-18
ES2297150T3 (es)	2008-05-01
EP2065384B1 (fr)	2011-01-05
EP1982984A2 (fr)	2008-10-22
CY2015029I1 (el)	2016-04-13
HK1070887A1 (en)	2005-06-30
TWI343919B (en)	2011-06-21
US7304078B2 (en)	2007-12-04
CY1107184T1 (el)	2012-10-24
DK2065384T3 (da)	2011-05-02
KR101026929B1 (ko)	2011-04-04
EP1860106A1 (fr)	2007-11-28
CY1111363T1 (el)	2015-08-05
EP2062890B1 (fr)	2011-01-05
IL164585A (en)	2010-11-30
DK1495018T3 (da)	2008-02-18
CY2015029I2 (el)	2016-04-13
CN1659162B (zh)	2011-08-31
CA2482858C (fr)	2010-11-30
EP1982984A3 (fr)	2008-10-29
SI1495018T1 (sl)	2008-04-30
HK1123302A1 (en)	2009-06-12
SI2065384T1 (sl)	2011-05-31
US20070179187A1 (en)	2007-08-02
EP1860106B1 (fr)	2010-01-20
AR039570A1 (es)	2005-02-23
US20030216437A1 (en)	2003-11-20
BR0309309A (pt)	2005-02-15
PL214718B1 (pl)	2013-09-30
DE60335679D1 (de)	2011-02-17
SG164279A1 (en)	2010-09-29
EP2062890A1 (fr)	2009-05-27
PE20040412A1 (es)	2004-07-12
JP2005528406A (ja)	2005-09-22
KR20040099441A (ko)	2004-11-26
NO330500B1 (no)	2011-05-02
US7713999B2 (en)	2010-05-11
FR15C0047I2 (fr)	2016-05-06
ECSP045368A (es)	2005-01-03
CN1659162A (zh)	2005-08-24
DE60317493D1 (en)	2011-01-13
NO2015016I1 (no)	2015-07-20
NZ535880A (en)	2007-11-30
CA2482858A1 (fr)	2003-10-30
RU2004133375A (ru)	2005-07-10
PT1495018E (pt)	2008-02-19
ZA200408342B (en)	2006-05-31
EP1495018A1 (fr)	2005-01-12
EP1495018B3 (fr)	2011-03-16
MXPA04010308A (es)	2005-02-03
NO2015016I2 (no)	2015-07-09
MY144040A (en)	2011-07-29
DE60317493T3 (de)	2018-07-12
ES2357876T3 (es)	2011-05-03
TW200404068A (en)	2004-03-16
AU2003221932A1 (en)	2003-11-03
WO2003089428A1 (fr)	2003-10-30
EP1495018B1 (fr)	2007-11-14
ES2338171T3 (es)	2010-05-04
ATE378330T1 (de)	2007-11-15
ES2297150T7 (es)	2012-03-16
NL300746I2 (fr)	2016-01-21
RU2329264C9 (ru)	2009-04-20
JP2010132710A (ja)	2010-06-17
ATE494284T1 (de)	2011-01-15
DE60317493T2 (de)	2008-09-18
EP1982984B1 (fr)	2013-02-13
US20070270439A1 (en)	2007-11-22
NO20044963L (no)	2004-11-15
FR15C0047I1 (fr)	2015-08-28
NL300746I1 (fr)	2016-01-21
RU2329264C2 (ru)	2008-07-20
JP4558331B2 (ja)	2010-10-06
BRPI0309309B8 (pt)	2021-05-25
LTC1495018I2 (lt)	2017-04-10
PL373332A1 (en)	2005-08-22
HK1129893A1 (en)	2009-12-11
NZ575139A (en)	2010-08-27
EP2065384A1 (fr)	2009-06-03
DE60331114D1 (de)	2010-03-11

Publication	Publication Date	Title
IL165841A0 (en)	2006-01-15	Mchir antagonists
GB0303210D0 (en)	2003-03-19	Early entry
GB0403532D0 (en)	2004-03-24	Early entry
PL376509A1 (en)	2005-12-27	Antagonists il-15
EP1500622A4 (fr)	2009-05-20	Ascenseur sans local de machinerie
IL163652A0 (en)	2005-12-18	Substituted hydroxyethylamines
AU153894S (en)	2003-12-01	Planer
GB2395048B (en)	2006-06-21	Interface devices
GB0207015D0 (en)	2002-05-08	Interface
GB0211257D0 (en)	2002-06-26	Novel heterocycles
DE50308027D1 (en)	2007-10-04	Cyclohexyl-harnstoff-derivate
AU2003300904A8 (en)	2004-07-09	Antagonists for human prolactin
PL372307A1 (en)	2005-07-11	Substituted 4-aminocyclohexanols
EP1580045A4 (fr)	2006-08-30	Monture superieure
GB0209608D0 (en)	2002-06-05	Early entry
IL166740A0 (en)	2006-01-15	Substituted heterocyclylpyrimidines
AU2003268504A8 (en)	2004-03-29	Whale-safe rope
GB0317960D0 (en)	2003-09-03	Early entry
GB0209989D0 (en)	2002-06-12	Novel heterocycles
GB0414710D0 (en)	2004-08-04	Thyristor
IL162534A0 (en)	2005-11-20	Novel alkansulfonamides as endotheline antagonists
GB0215389D0 (en)	2002-08-14	Receptor
GB0228658D0 (en)	2003-01-15	Planer
PL377325A1 (pl)	2006-01-23	Podstawione benzodioksepiny
AU152868S (en)	2003-08-22	An edger